Asymmetrical Methyltransferase PRMT3 Regulates Human Mesenchymal Stem Cell Osteogenesis Via Mir-3648.

Zhang Min,Liu Xiaomeng,Li Zheng,Du Yangge,Liu Xuejiao,Lv Longwei,Zhang Xiao,Liu Yunsong,Zhang Ping,Zhou Yongsheng
DOI: https://doi.org/10.1038/s41419-019-1815-7
2019-01-01
Cell Death and Disease
Abstract:Histone arginine methylation, which is catalyzed by protein arginine methyltransferases (PRMTs), plays a key regulatory role in various biological processes. Several PRMTs are involved in skeletal development; however, their role in the osteogenic differentiation of mesenchymal stem cells (MSCs) is not completely clear. In this study, we aimed to elucidate the function of PRMT3, a type-I PRMT that catalyzes the formation of ω-mono- or asymmetric dimethyl arginine, in MSCs osteogenesis. We found that PRMT3 promoted MSCs osteogenic commitment and bone remodeling. PRMT3 activated the expression of miR-3648 by enhancing histone H4 arginine 3 asymmetric dimethylation (H4R3me2a) levels at promoter region of the gene. Overexpression of miR-3648 rescued impaired osteogenesis in PRMT3-deficient cells. Moreover, administration of Prmt3 shRNA or a chemical inhibitor of PRMT3 (SGC707) caused an osteopenia phenotype in mice. These results indicate that PRMT3 is a potential therapeutic target for the treatment of bone regeneration and osteopenia disorders.
What problem does this paper attempt to address?